Media coverage about TrovaGene (NASDAQ:TROV) has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TrovaGene earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.0955360802268 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s scoring:
Shares of TrovaGene stock opened at $0.34 on Friday. The stock has a market capitalization of $19.24, a price-to-earnings ratio of -0.62 and a beta of -0.09. TrovaGene has a 52-week low of $0.23 and a 52-week high of $1.63.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings results on Monday, February 26th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. TrovaGene had a negative net margin of 4,932.08% and a negative return on equity of 315.63%. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million. sell-side analysts predict that TrovaGene will post -0.26 EPS for the current fiscal year.
TROV has been the subject of several research analyst reports. HC Wainwright initiated coverage on shares of TrovaGene in a research report on Thursday, December 21st. They issued a “buy” rating and a $1.00 target price for the company. Maxim Group reissued a “hold” rating on shares of TrovaGene in a research report on Wednesday, January 24th. Finally, ValuEngine raised shares of TrovaGene from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $2.50.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/trovagene-trov-earns-daily-media-sentiment-score-of-0-08.html.
TrovaGene Company Profile
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.